cyc-2.1 Antibody

Basic Research Questions

How to validate cyc-2.1 antibody specificity in C. elegans tissues?

• Methodology:

  • Perform tissue-specific RNAi knockdown using rde-1 rescue strains with germline-, intestine-, or muscle-specific promoters .

  • Compare antibody signal intensity via immunofluorescence or Western blot between control and cyc-2.1 RNAi-treated samples.

  • Validate using orthogonal methods (e.g., transcriptional reporters or CRISPR-Cas9-tagged cyc-2.1).

What protocols optimize cyc-2.1 detection in germline vs. somatic tissues?

• Key steps:

  • Fixation: Use 2% paraformaldehyde + 0.1% glutaraldehyde for germline preservation .

  • Antibody dilution: Test 1:100–1:500 ranges in PBS-T + 5% BSA.

  • Controls: Include cyc-2.1 null mutants or RNAi-treated samples to confirm signal reduction.

How to ensure reproducibility in lifespan assays involving cyc-2.1 inhibition?

• Experimental design:

  • Standardize RNAi conditions (e.g., HT115 E. coli strain, 20°C incubation) .

  • Include atfs-1 or aak-2 mutants as negative controls for UPRmt or AMPK dependency .

Advanced Research Questions

How to resolve contradictions in cyc-2.1’s role across genetic backgrounds?

• Case study: While cyc-2.1 RNAi extends lifespan in daf-2 mutants, it fails in daf-2 rsks-1 double mutants .

  • Approach:

    • Perform translational profiling to identify compensatory pathways in double mutants.

    • Quantify mitochondrial ROS and ATP levels to assess metabolic rewiring.

What methodologies confirm non-autonomous UPRmt activation by germline cyc-2.1 inhibition?

• Stepwise validation:

  • Use tissue-specific rde-1 rescue strains to restrict RNAi to the germline .

  • Monitor distal UPRmt activation in the intestine via hsp-6p::gfp reporters .

  • Perform RNA-seq on intestinal tissue to identify mitokine candidates (e.g., fmo-2).

How to design antibodies targeting isoform-specific cytochrome c variants?

• Engineering considerations:

  • Use CDR grafting from rodent antibodies to human frameworks for reduced immunogenicity .

  • Retain critical FR residues (e.g., positions 27–30 in heavy chain) to preserve affinity .

  • Validate cross-reactivity using C. elegans lysates and human cytochrome c paralogs.

Data Contradiction Analysis

Case: cyc-2.1 RNAi extends lifespan independently of cep-1/p53 but requires atfs-1 .

• Hypothesis testing:

  • Compare transcriptomes of cyc-2.1 RNAi-treated cep-1 vs. atfs-1 mutants.

  • Measure mitochondrial protein import efficiency via GFP-tagged matrix proteins.

• Resolution: UPRmt activation bypasses canonical apoptosis pathways, emphasizing ATFS-1’s role in stress signaling .

Methodological Best Practices

• Antibody validation: Include tissue-specific knockdowns and genetic null controls.

• Lifespan assays: Use ≥100 synchronized animals per condition and repeat 3× .

• Statistical thresholds: Apply Bonferroni correction for multi-tissue RNAi experiments.